RV 158

A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults

Trial Details:

I Completed
U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR) July 01, 2005
MVA-CMDR Viral Vector - Pox
Thailand, USA 48